Core Viewpoint - The article highlights the serious threat posed by "reflow drugs," which are pharmaceuticals that re-enter the market through unofficial channels, jeopardizing consumer safety and undermining the integrity of the healthcare system [1][2]. Group 1: Impact on Consumer Safety and Market Integrity - Reflow drugs pose significant risks to public health, as they may be expired or stored improperly, leading to ineffective treatment or worsening of conditions [2]. - The presence of reflow drugs disrupts the legitimate pharmaceutical market, harming the interests of legitimate companies and eroding healthcare funds [2]. - The unique traceability codes on drug packages serve as a safeguard against counterfeit and reflow drugs, with multiple scans indicating potential fraud [2]. Group 2: Law Enforcement and Regulatory Actions - The National Healthcare Security Administration has initiated a special action to combat the sale of reflow drugs, uncovering over 30,000 suspicious traceability code leads across various institutions [2][7]. - Notable cases include a pharmacy in Hunan that sold drugs with traceability codes linked to multiple regions, raising concerns about the legitimacy of their inventory [2]. - The article details organized crime involving reflow drugs, with significant financial implications, including cases where criminal groups operated across regions with transactions exceeding 100 million yuan [3]. Group 3: Mechanisms of Reflow Drug Distribution - The article outlines the methods by which reflow drugs are sold, including individuals purchasing drugs through insurance and reselling them, as well as collusion between drug dealers and pharmacies [4]. - A specific case illustrates how an individual exploited insurance accounts to sell drugs at below-market prices, leading to legal consequences [4][11]. - The article also describes how some pharmaceutical companies engage in fraudulent practices, such as falsifying invoices to disguise reflow drugs as legitimate products [5][12]. Group 4: Regulatory Framework and Future Measures - The establishment of a comprehensive drug traceability system is underway, with all medical institutions required to upload traceability data by January 2026 [7]. - The article notes that as of August, over 661.51 billion traceability codes have been collected, indicating a tightening regulatory framework against reflow drugs [7]. - Experts suggest that a unified data standard and deeper integration of regulatory platforms are necessary to effectively combat the issue of reflow drugs [8]. Group 5: Public Awareness and Legal Consequences - The article emphasizes the importance of public engagement in monitoring drug sales through traceability codes to ensure safety and protect healthcare funds [9]. - Legal experts advocate for stricter definitions and penalties for those involved in the reflow drug trade, including potential inclusion on blacklists for offenders [9]. - The article concludes that the current regulatory environment presents low costs for offenders and high costs for enforcement, necessitating legal reforms to deter such activities [9].

Core Insights - The provincial medical insurance flying inspections are being initiated across various regions, focusing on the issue of "return drugs" and fraudulent practices in medical insurance [1][2][3] Group 1: Inspection Overview - The provincial flying inspections will cover all medical service behaviors and costs from January 1, 2023, to December 31, 2024, with the possibility of extending checks to previous years or 2025 [1] - The inspections are organized in a collaborative manner involving provincial and municipal levels, with teams typically consisting of around 50 members, including experts from various fields [2] Group 2: Focus Areas - Key areas of inspection include medical institutions, retail pharmacies, insured individuals, and medical insurance handling agencies, with specific attention on self-inspection results in nine medical fields [3] - The "return drug" issue is highlighted, with a focus on tracking drug traceability codes to combat illegal resale practices [3][4] Group 3: Regulatory Actions - The inspections will lead to immediate reporting to drug regulatory authorities for any discovered illegal activities, including the sale of return drugs and counterfeit medications [4] - The National Medical Insurance Administration has previously recovered over 8 billion yuan through similar inspections, demonstrating the effectiveness of these regulatory measures [2]